People | December 06, 2022
Biocon Biologics elevates Shreehas Tambe as MD & CEO
Tambe has been with Biocon since 1997 and has held diverse leadership and operational roles.
Tambe has been with Biocon since 1997 and has held diverse leadership and operational roles.
BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets
Express Scripts, a leading pharmacy benefit management organization, will list Viatris labelled biosimilar insulin Glargine as a preferred insulin brand on its National Preferred Formulary (NPF)
Dr Christiane Hamacher, has stepped down as the MD of Biocon Biologics and will be succeeded by Dr Arun Chandavarkar.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)